563 related articles for article (PubMed ID: 17342411)
21. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.
Siddiq A; Ayoub IA; Chavez JC; Aminova L; Shah S; LaManna JC; Patton SM; Connor JR; Cherny RA; Volitakis I; Bush AI; Langsetmo I; Seeley T; Gunzler V; Ratan RR
J Biol Chem; 2005 Dec; 280(50):41732-43. PubMed ID: 16227210
[TBL] [Abstract][Full Text] [Related]
22. Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases.
Chan MC; Ilott NE; Schödel J; Sims D; Tumber A; Lippl K; Mole DR; Pugh CW; Ratcliffe PJ; Ponting CP; Schofield CJ
J Biol Chem; 2016 Sep; 291(39):20661-73. PubMed ID: 27502280
[TBL] [Abstract][Full Text] [Related]
23. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.
Berra E; Benizri E; Ginouvès A; Volmat V; Roux D; Pouysségur J
EMBO J; 2003 Aug; 22(16):4082-90. PubMed ID: 12912907
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of a viral prolyl hydroxylase.
Langley GW; Abboud MI; Lohans CT; Schofield CJ
Bioorg Med Chem; 2019 Jun; 27(12):2405-2412. PubMed ID: 30737136
[TBL] [Abstract][Full Text] [Related]
25. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
26. Molecular characterization and mRNA expression of two key enzymes of hypoxia-sensing pathways in eastern oysters Crassostrea virginica (Gmelin): hypoxia-inducible factor α (HIF-α) and HIF-prolyl hydroxylase (PHD).
Piontkivska H; Chung JS; Ivanina AV; Sokolov EP; Techa S; Sokolova IM
Comp Biochem Physiol Part D Genomics Proteomics; 2011 Jun; 6(2):103-14. PubMed ID: 21106446
[TBL] [Abstract][Full Text] [Related]
27. Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response.
Kuiper C; Dachs GU; Currie MJ; Vissers MC
Free Radic Biol Med; 2014 Apr; 69():308-17. PubMed ID: 24495550
[TBL] [Abstract][Full Text] [Related]
28. Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation--implications for prolyl hydroxylase activity and iron.
Callapina M; Zhou J; Schnitzer S; Metzen E; Lohr C; Deitmer JW; Brüne B
Exp Cell Res; 2005 May; 306(1):274-84. PubMed ID: 15878351
[TBL] [Abstract][Full Text] [Related]
29. Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.
Giatromanolaki A; Koukourakis MI; Pezzella F; Turley H; Sivridis E; Bouros D; Bougioukas G; Harris AL; Gatter KC
Cancer Lett; 2008 Apr; 262(1):87-93. PubMed ID: 18187257
[TBL] [Abstract][Full Text] [Related]
30. [The new face of factors induced by hypoxia--HIF-1 and HIF-2 and oxidative stress].
Stachurska A; Florczyk U; Józkowicz A; Dulak J; Łoboda A
Postepy Biochem; 2010; 56(2):156-64. PubMed ID: 20873110
[TBL] [Abstract][Full Text] [Related]
31. Prolyl 4-hydroxylases, master regulators of the hypoxia response.
Myllyharju J
Acta Physiol (Oxf); 2013 Jun; 208(2):148-65. PubMed ID: 23489300
[TBL] [Abstract][Full Text] [Related]
32. Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD.
Tanaka T; Nangaku M
J Pharmacol Sci; 2009 Jan; 109(1):24-31. PubMed ID: 19151537
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases.
Koivunen P; Serpi R; Dimova EY
Pharmacol Res; 2016 Dec; 114():265-273. PubMed ID: 27832958
[TBL] [Abstract][Full Text] [Related]
34. Effects of prolyl hydroxylase inhibitors on adipogenesis and hypoxia inducible factor 1 alpha levels under normoxic conditions.
Floyd ZE; Kilroy G; Wu X; Gimble JM
J Cell Biochem; 2007 Aug; 101(6):1545-57. PubMed ID: 17370314
[TBL] [Abstract][Full Text] [Related]
35. Role and regulation of prolyl hydroxylase domain proteins.
Fong GH; Takeda K
Cell Death Differ; 2008 Apr; 15(4):635-41. PubMed ID: 18259202
[TBL] [Abstract][Full Text] [Related]
36. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.
Pan Y; Mansfield KD; Bertozzi CC; Rudenko V; Chan DA; Giaccia AJ; Simon MC
Mol Cell Biol; 2007 Feb; 27(3):912-25. PubMed ID: 17101781
[TBL] [Abstract][Full Text] [Related]
37. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.
Brahimi-Horn C; Pouysségur J
Bull Cancer; 2006 Aug; 93(8):E73-80. PubMed ID: 16935775
[TBL] [Abstract][Full Text] [Related]
38. Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors.
Henze AT; Riedel J; Diem T; Wenner J; Flamme I; Pouyseggur J; Plate KH; Acker T
Cancer Res; 2010 Jan; 70(1):357-66. PubMed ID: 20028863
[TBL] [Abstract][Full Text] [Related]
39. Prolyl-4-hydroxylase 2 and 3 coregulate murine erythropoietin in brain pericytes.
Urrutia AA; Afzal A; Nelson J; Davidoff O; Gross KW; Haase VH
Blood; 2016 Nov; 128(21):2550-2560. PubMed ID: 27683416
[TBL] [Abstract][Full Text] [Related]
40. Endogenous 2-oxoglutarate levels impact potencies of competitive HIF prolyl hydroxylase inhibitors.
Thirstrup K; Christensen S; Møller HA; Ritzén A; Bergström AL; Sager TN; Jensen HS
Pharmacol Res; 2011 Sep; 64(3):268-73. PubMed ID: 21504793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
